# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Gil Blum reiterates NextCure (NASDAQ:NXTC) with a Buy and maintains $4 price target.
NextCure (NASDAQ:NXTC) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.38) by...
HC Wainwright & Co. analyst Emily Bodnar reiterates NextCure (NASDAQ:NXTC) with a Buy and maintains $8 price target.
HC Wainwright & Co. analyst Emily Bodnar reiterates NextCure (NASDAQ:NXTC) with a Buy and maintains $8 price target.
Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease co...
HC Wainwright & Co. analyst Emily Bodnar reiterates NextCure (NASDAQ:NXTC) with a Buy and maintains $8 price target.
Needham analyst Gil Blum reiterates NextCure (NASDAQ:NXTC) with a Buy and maintains $4 price target.
NextCure (NASDAQ:NXTC) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.59) by...